Hyloris Pharmaceuticals S.A.
Research Hyloris Pharmaceuticals S.A. (0AB6) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- Ticker0AB6
- ExchangeLSE
- CountryBelgium
- CurrencyEUR
- Financial periodFY2025
- RevenueEUR 7.21M
- Revenue growth-14.8%
- Net income-EUR 6.33M
- Free cash flow-EUR 7.62M
- Gross margin94.7%
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 7.21M | -EUR 6.33M | -EUR 7.62M | 94.7% | -0.23 | EUR 13.78M | EUR 1.61M | EUR 26.48M |
| FY2024 | EUR 8.46M | -EUR 6.34M | -EUR 7.49M | 97.3% | -0.23 | EUR 23.59M | EUR 1.82M | EUR 32.14M |
| FY2023 | EUR 2.09M | -EUR 15.38M | -EUR 13.56M | 95.5% | -0.56 | EUR 30.41M | EUR 1.75M | EUR 39.07M |
| FY2022 | EUR 900.00K | -EUR 11.91M | -EUR 13.76M | 89.6% | -0.43 | EUR 33.46M | EUR 885.00K | EUR 53.91M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-10 | n/a | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Hyloris Pharmaceuticals S.A.
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias;
Related stock research
Other related stocks
Frequently asked questions
What does Hyloris Pharmaceuticals S.A. do?
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias; and Valacyclovir oral suspension for the treatment of herpes virus infections.